Loading...

GH R

GHRS

GH RESEARCH PLC

(GHRS)

2025 6-K

Clinical Trial Results

25 Mar '26

Fireside Chat Announcement

16 Mar '26

Financial Results Release

5 Mar '26

Panel Discussion Announcement

22 Jan '26

Filing Notification

15 Jan '26

Conference Participation

13 Jan '26

Clinical Trials Presentation

8 Jan '26

FDA Hold Lifted

5 Jan '26

6-K Filing

2 Jan '26

Presentation Acceptance

24 Nov '25

Investor Conference Partici...

7 Nov '25

Q3 Financial Results

6 Nov '25

Clinical Trial Update

17 Oct '25

Data Presentation Announcement

14 Oct '25

Clinical Trial Presentation

10 Oct '25

Event Announcement

9 Oct '25

Fireside Chat Announcement

12 Sep '25

Clinical Data Presentation

9 Sep '25

Investor Conference

29 Aug '25

Financial Results Update

7 Aug '25

Annual Meeting Update

1 Aug '25

Program Development Update

23 Jul '25

Clinical Hold Update

20 Jun '25

Annual Meeting Notice

18 Jun '25

Investor Meetings

13 Jun '25

Conference Announcement

27 May '25

Congress Presentation Annou...

21 May '25

Pipeline Presentation

15 May '25

Earnings Report

8 May '25

Investor Meetings

27 Feb '25

Share Offering Completed

6 Feb '25

GH Research Update

4 Feb '25

Filing Announcement

3 Feb '25

Company Update

3 Feb '25

Clinical Trial Update

3 Feb '25

Filing Report

31 Jan '25

Research Progress Update

10 Jan '25

Event Announcement

5 Dec '24

Financial Results Update

14 Nov '24

Company Event Announcement

20 Sep '24

Investor Meetings

16 Sep '24

Investor Meetings

9 Sep '24

Investor Meetings Announcement

3 Sep '24

CEO Appointment

3 Sep '24

Financial Results Update

3 Sep '24

Annual Meeting Outcomes

28 Jun '24

Investor Meetings Scheduled

24 Jun '24

Annual Meeting Notice

15 May '24

Quarterly Financial Results

3 May '24

Investor Meetings

10 Apr '24

Investor Meetings

15 Mar '24

Investor Conference Partici...

29 Feb '24

Filing Announcement

18 Jan '24

Investor Meetings Scheduled

5 Jan '24

External Links:

SEC

On February 3, 2025, GH Research PLC announced that its Phase 2b trial for GH001, an inhalable mebufotenin for treatment-resistant depression, met its primary endpoint. They will also host a conference call to discuss the findings.

AI Assistant

GH RESEARCH PLC

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.